NASDAQ:ESPR - Esperion Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $49.27
  • Forecasted Upside: 215.85 %
  • Number of Analysts: 10
  • Breakdown:
  • 2 Sell Ratings
  • 5 Hold Ratings
  • 2 Buy Ratings
  • 1 Strong Buy Ratings
▼ -1.19 (-7.09%)

This chart shows the closing price for ESPR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Esperion Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ESPR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ESPR

Analyst Price Target is $49.27
▲ +215.85% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Esperion Therapeutics in the last 3 months. The average price target is $49.27, with a high forecast of $134.00 and a low forecast of $20.00. The average price target represents a 215.85% upside from the last price of $15.60.

This chart shows the closing price for ESPR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 10 contributing investment analysts is to hold stock in Esperion Therapeutics. This rating has held steady since January 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 2 sell ratings
  • 1 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 2 sell ratings
  • 1 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 2 sell ratings
  • 1 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 1 sell ratings
  • 1 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 1 sell ratings
  • 1 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 2 sell ratings
  • 1 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 2 sell ratings
  • 1 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 2 sell ratings

Latest Recommendations

  • 1 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/11/2021Stifel NicolausReiterated RatingBuy ➝ Hold$37.00 ➝ $20.00Low
5/5/2021BTIG ResearchLower Price Target$90.00 ➝ $71.00High
5/5/2021Northland SecuritiesLower Price TargetMarket Perform$30.00 ➝ $24.00High
5/5/2021Credit Suisse GroupLower Price TargetOutperform$45.00 ➝ $36.00High
5/5/2021Morgan StanleyLower Price TargetEqual Weight$30.00 ➝ $22.00High
5/5/2021JMP SecuritiesLower Price TargetMarket Outperform$191.00 ➝ $111.00High
5/5/2021Stifel NicolausDowngradeBuy ➝ Hold$37.00 ➝ $20.00High
3/11/2021Morgan StanleyInitiated CoverageEqual Weight$30.00Medium
2/25/2021Needham & Company LLCLower Price TargetStrong-Buy$150.00 ➝ $134.00High
2/12/2021Jefferies Financial GroupDowngradeBuy ➝ Hold$40.00 ➝ $30.00Low
2/9/2021The Goldman Sachs GroupDowngradeNeutral ➝ Sell$44.00 ➝ $24.00Low
1/15/2021Bank of AmericaDowngradeBuy ➝ Neutral$52.00 ➝ $35.00High
11/10/2020Credit Suisse GroupUpgradeNeutral ➝ Outperform$45.00Medium
10/15/2020Bank of AmericaLower Price TargetBuy$55.00 ➝ $52.00Low
9/29/2020JPMorgan Chase & Co.Initiated CoverageSell$35.00Low
8/17/2020Bank of AmericaLower Price TargetBuy$60.00 ➝ $55.00Low
8/11/2020Needham & Company LLCReiterated RatingBuy$158.00High
8/10/2020Stifel NicolausReiterated RatingBuy$75.00High
8/10/2020Credit Suisse GroupDowngradeOutperform ➝ Neutral$83.00 ➝ $45.00High
6/29/2020Credit Suisse GroupInitiated CoverageBuy$83.00High
6/26/2020Stifel NicolausReiterated RatingBuy$75.00High
6/23/2020Northland SecuritiesInitiated CoverageHold$42.00High
6/9/2020Credit Suisse GroupReiterated RatingBuy$87.00Medium
5/7/2020Jefferies Financial GroupLower Price TargetBuy$85.00 ➝ $70.00High
5/7/2020Needham & Company LLCReiterated RatingBuyHigh
5/7/2020Northland SecuritiesReiterated RatingHold$42.00High
5/7/2020CitigroupBoost Price TargetBuy$46.00 ➝ $56.00High
5/6/2020Stifel NicolausReiterated RatingBuy$76.00High
4/20/2020Stifel NicolausReiterated RatingBuyLow
4/20/2020Needham & Company LLCReiterated RatingBuy$158.00Low
4/16/2020Northland SecuritiesLower Price TargetMarket Perform$60.00 ➝ $42.00High
4/6/2020Needham & Company LLCReiterated RatingBuy$158.00High
4/1/2020Bank of AmericaInitiated CoverageBuy$50.00High
3/31/2020Needham & Company LLCReiterated RatingBuy$158.00High
3/17/2020CitigroupUpgradeNeutral ➝ BuyHigh
2/28/2020JPMorgan Chase & Co.Boost Price TargetNeutral$46.00 ➝ $47.00Low
2/27/2020CowenReiterated RatingBuy$87.00Medium
2/24/2020Needham & Company LLCBoost Price TargetStrong-Buy$144.00 ➝ $158.00Medium
2/24/2020JMP SecuritiesReiterated RatingOutperform$191.00Medium
2/23/2020Stifel NicolausReiterated RatingBuy$83.00Medium
2/23/2020Northland SecuritiesDowngradeOutperform ➝ Market Perform$60.00Medium
2/19/2020BTIG ResearchReiterated RatingBuy$90.00Medium
2/14/2020CitigroupDowngradeBuy ➝ Neutral$73.00 ➝ $82.00High
1/31/2020Chardan CapitalReiterated RatingHold$65.00High
11/6/2019CowenReiterated RatingBuyLow
9/17/2019Stifel NicolausLower Price TargetBuy$112.00 ➝ $70.00Low
9/16/2019The Goldman Sachs GroupUpgradeSell ➝ Neutral$55.00 ➝ $45.00Medium
8/29/2019Northland SecuritiesReiterated RatingBuyHigh
8/8/2019Northland SecuritiesReiterated RatingBuyMedium
7/18/2019CowenReiterated RatingBuy$80.00Low
6/14/2019Northland SecuritiesSet Price TargetBuy$65.00Medium
6/13/2019Stifel NicolausReiterated RatingBuyLow
6/13/2019CowenReiterated RatingBuy$85.00Medium
5/29/2019The Goldman Sachs GroupDowngradeNeutral ➝ Sell$50.00Medium
5/28/2019CitigroupSet Price TargetBuy$73.00High
5/6/2019Credit Suisse GroupBoost Price TargetOutperform$79.00 ➝ $90.00Medium
5/6/2019Bank of AmericaUpgradeUnderperform ➝ NeutralLow
5/5/2019CowenSet Price TargetBuy$94.00High
4/26/2019The Goldman Sachs GroupUpgradeSell ➝ Neutral$50.00Low
4/2/2019Northland SecuritiesSet Price TargetBuy$65.00Low
3/29/2019Stifel NicolausReiterated RatingBuy$112.00Low
3/14/2019Chardan CapitalReiterated RatingHold$50.00Medium
3/13/2019JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$38.00 ➝ $47.00High
3/1/2019Northland SecuritiesReiterated RatingBuy$65.00Low
1/15/2019CowenReiterated RatingBuy$94.00Low
1/7/2019Needham & Company LLCBoost Price TargetStrong-Buy$94.00 ➝ $114.00Low
12/13/2018The Goldman Sachs GroupInitiated CoverageSell ➝ Sell$45.00High
12/10/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$89.00 ➝ $104.00Medium
10/29/2018Northland SecuritiesUpgradeMarket Perform ➝ Outperform$65.00High
10/26/2018CowenSet Price TargetBuy$82.00Low
10/16/2018BTIG ResearchInitiated CoverageBuy ➝ Buy$82.00High
9/14/2018Stifel NicolausInitiated CoverageBuy$89.00High
8/17/2018CitigroupUpgradeNeutral ➝ Buy$57.00 ➝ $75.00Low
8/6/2018CowenReiterated RatingBuy$95.00Low
7/20/2018Chardan CapitalUpgradeHold$32.50Low
7/11/2018Northland SecuritiesDowngradeOutperform ➝ Market PerformMedium
5/16/2018UBS GroupSet Price TargetBuy$90.00 ➝ $75.00Low
5/4/2018Credit Suisse GroupLower Price TargetOutperform ➝ Outperform$108.00 ➝ $73.00N/A
5/3/2018JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$100.54 ➝ $41.00High
5/3/2018Deutsche Bank AktiengesellschaftLower Price TargetBuy ➝ Buy$100.00 ➝ $75.00High
5/2/2018Bank of AmericaReiterated RatingBuy ➝ UnderperformHigh
4/19/2018Northland SecuritiesBoost Price TargetBuy$100.00 ➝ $121.00Low
3/27/2018Chardan CapitalBoost Price TargetNeutral ➝ Neutral$75.00 ➝ $100.00Low
3/9/2018Deutsche Bank AktiengesellschaftBoost Price TargetBuy$100.00Low
3/8/2018JMP SecuritiesBoost Price TargetOutperform$60.00 ➝ $153.00High
3/7/2018Stifel NicolausSet Price TargetBuy$105.00High
2/21/2018UBS GroupSet Price TargetNeutral ➝ Neutral$88.00 ➝ $90.00High
2/21/2018JPMorgan Chase & Co.Reiterated RatingNeutral ➝ Neutral$55.00 ➝ $65.00High
2/21/2018Needham & Company LLCReiterated RatingStrong-Buy ➝ Strong-Buy$81.00 ➝ $94.00Low
1/22/2018CitigroupDowngradeBuy ➝ Neutral$77.00 ➝ $96.00Low
1/17/2018Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$103.00Low
1/17/2018UBS GroupSet Price TargetBuy ➝ Buy$62.00 ➝ $88.00High
1/15/2018Stifel NicolausSet Price TargetPositive ➝ Buy$70.00 ➝ $105.00Medium
1/5/2018Bank of AmericaUpgradeNeutral ➝ Buy$76.00High
12/14/2017Needham & Company LLCUpgradeBuy ➝ Strong-Buy$72.00 ➝ $81.00Medium
12/6/2017Chardan CapitalBoost Price TargetNeutral$20.00 ➝ $75.00High
12/5/2017Chardan CapitalReiterated RatingNeutral ➝ Neutral$20.00 ➝ $75.00High
11/10/2017Northland SecuritiesReiterated RatingBuy$72.00N/A
10/4/2017Stifel NicolausReiterated RatingBuy$70.00Medium
10/4/2017Northland SecuritiesReiterated RatingBuy$72.00Medium
9/7/2017CowenInitiated CoverageOutperform$64.00Low
8/29/2017Northland SecuritiesInitiated CoverageOutperform ➝ Outperform$72.00Medium
8/21/2017Jefferies Financial GroupReiterated RatingBuy$85.00Low
8/11/2017Bank of AmericaReiterated RatingNeutral ➝ Neutral$60.00Medium
8/10/2017Stifel NicolausReiterated RatingBuy$60.00 ➝ $70.00High
8/9/2017Deutsche Bank AktiengesellschaftSet Price TargetBuy$48.00 ➝ $64.00High
8/8/2017Jefferies Financial GroupUpgradeHold ➝ Buy$85.00 ➝ $55.00Low
8/8/2017Needham & Company LLCBoost Price TargetBuy ➝ Positive$58.00 ➝ $72.00High
7/10/2017Jefferies Financial GroupInitiated CoverageHold ➝ Hold$55.00Low
6/27/2017UBS GroupReiterated RatingBuy$52.00 ➝ $57.00N/A
6/26/2017Stifel NicolausReiterated RatingBuy ➝ Buy$45.00 ➝ $60.00Low
6/23/2017Deutsche Bank AktiengesellschaftInitiated CoverageBuy$48.00High
6/22/2017CitigroupReiterated RatingBuyHigh
3/29/2017UBS GroupUpgradeNeutral ➝ Buy$23.00 ➝ $52.00N/A
3/21/2017CitigroupBoost Price Target$77.00High
3/21/2017JPMorgan Chase & Co.Boost Price Target$22.00 ➝ $50.00High
3/20/2017JPMorgan Chase & Co.Reiterated RatingHold$22.00 ➝ $50.00Medium
3/20/2017CitigroupSet Price TargetBuy$39.00Medium
3/20/2017Royal Bank of CanadaReiterated RatingHold$45.00High
3/20/2017Needham & Company LLCBoost Price TargetStrong-Buy ➝ Strong-Buy$25.00 ➝ $58.00High
3/20/2017Credit Suisse GroupUpgradeUnderperform ➝ Neutral$29.00High
3/18/2017Needham & Company LLCSet Price TargetBuy$25.00High
3/13/2017CitigroupSet Price TargetBuy$39.00Low
2/28/2017CitigroupUpgradeNeutral ➝ Buy$14.00 ➝ $39.00N/A
2/23/2017Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$20.00 ➝ $30.00N/A
2/16/2017UBS GroupBoost Price TargetNeutral$11.00 ➝ $23.00N/A
2/7/2017Royal Bank of CanadaSet Price TargetHold$20.00N/A
2/4/2017Needham & Company LLCSet Price TargetBuy$25.00N/A
1/10/2017Needham & Company LLCReiterated RatingBuy$25.00N/A
1/3/2017Royal Bank of CanadaReiterated RatingHold$15.00N/A
12/20/2016Credit Suisse GroupReiterated RatingSell$12.00N/A
11/14/2016CitigroupDowngradeBuy ➝ NeutralN/A
11/6/2016JMP SecuritiesReiterated RatingBuyN/A
10/15/2016Stifel NicolausReiterated RatingBuy$64.00 ➝ $30.00N/A
10/15/2016Chardan CapitalReiterated RatingNeutral$12.50N/A
10/14/2016Credit Suisse GroupBoost Price TargetUnderperform$10.00 ➝ $14.00N/A
10/13/2016Chardan CapitalSet Price TargetHold$13.00N/A
9/22/2016Stifel NicolausReiterated RatingBuy$64.00N/A
8/31/2016BarclaysSet Price TargetHold$13.00N/A
8/5/2016JPMorgan Chase & Co.Set Price TargetHold$15.00N/A
(Data available from 7/25/2016 forward)
Esperion Therapeutics logo
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States and internationally. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Read More

Today's Range

Now: $15.60
Low: $15.55
High: $17.00

50 Day Range

MA: $20.94
Low: $15.60
High: $26.37

52 Week Range

Now: $15.60
Low: $15.55
High: $43.74


836,528 shs

Average Volume

536,132 shs

Market Capitalization

$439.76 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Esperion Therapeutics?

The following Wall Street research analysts have issued stock ratings on Esperion Therapeutics in the last year: Bank of America Co., BTIG Research, Credit Suisse Group AG, Jefferies Financial Group Inc., JMP Securities, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Northland Securities, Stifel Nicolaus, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for ESPR.

What is the current price target for Esperion Therapeutics?

11 Wall Street analysts have set twelve-month price targets for Esperion Therapeutics in the last year. Their average twelve-month price target is $49.27, suggesting a possible upside of 215.9%. Needham & Company LLC has the highest price target set, predicting ESPR will reach $134.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $20.00 for Esperion Therapeutics in the next year.
View the latest price targets for ESPR.

What is the current consensus analyst rating for Esperion Therapeutics?

Esperion Therapeutics currently has 2 sell ratings, 5 hold ratings, 2 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ESPR, but not buy more shares or sell existing shares.
View the latest ratings for ESPR.

What other companies compete with Esperion Therapeutics?

How do I contact Esperion Therapeutics' investor relations team?

Esperion Therapeutics' physical mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The biopharmaceutical company's listed phone number is 734-887-3903 and its investor relations email address is [email protected] The official website for Esperion Therapeutics is